Logo image of PAVM

PAVMED INC (PAVM) Stock Fundamental Analysis

USA - NASDAQ:PAVM - US70387R4039 - Common Stock

0.4201 USD
-0.01 (-1.82%)
Last: 9/12/2025, 8:06:57 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PAVM. PAVM was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PAVM have multiple concerns. PAVM is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PAVM had positive earnings in the past year.
In the past year PAVM has reported a negative cash flow from operations.
In the past 5 years PAVM reported 4 times negative net income.
PAVM had a negative operating cash flow in each of the past 5 years.
PAVM Yearly Net Income VS EBIT VS OCF VS FCFPAVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of 137.15%, PAVM belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
PAVM has a Return On Equity of 154.17%. This is amongst the best in the industry. PAVM outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 137.15%
ROE 154.17%
ROIC N/A
ROA(3y)-87.06%
ROA(5y)-98.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PAVM Yearly ROA, ROE, ROICPAVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin of PAVM (3635.17%) is better than 100.00% of its industry peers.
PAVM does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 3635.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PAVM Yearly Profit, Operating, Gross MarginsPAVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

PAVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
PAVM has more shares outstanding than it did 1 year ago.
PAVM has less shares outstanding than it did 5 years ago.
PAVM has a better debt/assets ratio than last year.
PAVM Yearly Shares OutstandingPAVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PAVM Yearly Total Debt VS Total AssetsPAVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PAVM has an Altman-Z score of -7.71. This is a bad value and indicates that PAVM is not financially healthy and even has some risk of bankruptcy.
PAVM's Altman-Z score of -7.71 is on the low side compared to the rest of the industry. PAVM is outperformed by 73.30% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that PAVM is not too dependend on debt financing.
PAVM has a Debt to Equity ratio (0.14) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -7.71
ROIC/WACCN/A
WACC6.08%
PAVM Yearly LT Debt VS Equity VS FCFPAVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PAVM has a Current Ratio of 0.37. This is a bad value and indicates that PAVM is not financially healthy enough and could expect problems in meeting its short term obligations.
PAVM's Current ratio of 0.37 is on the low side compared to the rest of the industry. PAVM is outperformed by 93.72% of its industry peers.
PAVM has a Quick Ratio of 0.37. This is a bad value and indicates that PAVM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of PAVM (0.37) is worse than 93.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
PAVM Yearly Current Assets VS Current LiabilitesPAVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

8

3. Growth

3.1 Past

PAVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.58%, which is quite impressive.
PAVM shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.15%.
Measured over the past years, PAVM shows a very strong growth in Revenue. The Revenue has been growing by 81.61% on average per year.
EPS 1Y (TTM)116.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.82%
Revenue 1Y (TTM)22.15%
Revenue growth 3Y81.61%
Revenue growth 5YN/A
Sales Q2Q%-99.39%

3.2 Future

Based on estimates for the next years, PAVM will show a very strong growth in Earnings Per Share. The EPS will grow by 26.79% on average per year.
The Revenue is expected to grow by 142.05% on average over the next years. This is a very strong growth
EPS Next Y108.83%
EPS Next 2Y26.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-96.01%
Revenue Next 2Y-63.49%
Revenue Next 3Y268.29%
Revenue Next 5Y142.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PAVM Yearly Revenue VS EstimatesPAVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
PAVM Yearly EPS VS EstimatesPAVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10 -15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PAVM is valuated cheaply with a Price/Earnings ratio of 0.32.
Based on the Price/Earnings ratio, PAVM is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. PAVM is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PAVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.32
Fwd PE N/A
PAVM Price Earnings VS Forward Price EarningsPAVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PAVM Per share dataPAVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PAVM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PAVM's earnings are expected to grow with 26.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y26.79%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PAVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAVMED INC

NASDAQ:PAVM (9/12/2025, 8:06:57 PM)

0.4201

-0.01 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11
Inst Owners7.06%
Inst Owner Change1.08%
Ins Owners5.92%
Ins Owner Change0%
Market Cap8.93M
Analysts82.5
Price Target11.73 (2692.19%)
Short Float %1.01%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)253.15%
Min EPS beat(2)149.88%
Max EPS beat(2)356.41%
EPS beat(4)3
Avg EPS beat(4)124.37%
Min EPS beat(4)-28.52%
Max EPS beat(4)356.41%
EPS beat(8)5
Avg EPS beat(8)57.89%
EPS beat(12)7
Avg EPS beat(12)37.75%
EPS beat(16)7
Avg EPS beat(16)22.99%
Revenue beat(2)0
Avg Revenue beat(2)-59.94%
Min Revenue beat(2)-98.31%
Max Revenue beat(2)-21.57%
Revenue beat(4)0
Avg Revenue beat(4)-37.71%
Min Revenue beat(4)-98.31%
Max Revenue beat(4)-10.67%
Revenue beat(8)1
Avg Revenue beat(8)-26.23%
Revenue beat(12)2
Avg Revenue beat(12)-35.64%
Revenue beat(16)2
Avg Revenue beat(16)-40.39%
PT rev (1m)0%
PT rev (3m)-2.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.14%
EPS NY rev (1m)0%
EPS NY rev (3m)131.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.32
Fwd PE N/A
P/S 4.48
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)1.33
EY316.59%
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.09
BVpS2.21
TBVpS2.21
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 137.15%
ROE 154.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3635.17%
GM N/A
FCFM N/A
ROA(3y)-87.06%
ROA(5y)-98.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.9%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -7.71
F-Score4
WACC6.08%
ROIC/WACCN/A
Cap/Depr(3y)25.15%
Cap/Depr(5y)202.92%
Cap/Sales(3y)138.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.82%
EPS Next Y108.83%
EPS Next 2Y26.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.15%
Revenue growth 3Y81.61%
Revenue growth 5YN/A
Sales Q2Q%-99.39%
Revenue Next Year-96.01%
Revenue Next 2Y-63.49%
Revenue Next 3Y268.29%
Revenue Next 5Y142.05%
EBIT growth 1Y42.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.64%
OCF growth 3YN/A
OCF growth 5YN/A